Compare BLBD & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | MESO |
|---|---|---|
| Founded | 1927 | 2004 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | N/A | N/A |
| Metric | BLBD | MESO |
|---|---|---|
| Price | $47.85 | $19.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $64.60 | $24.00 |
| AVG Volume (30 Days) | ★ 370.9K | 218.0K |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.79 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $1,480,099,000.00 | $17,198,000.00 |
| Revenue This Year | $4.86 | $576.59 |
| Revenue Next Year | $3.41 | $41.15 |
| P/E Ratio | $12.13 | ★ N/A |
| Revenue Growth | 9.87 | ★ 191.39 |
| 52 Week Low | $30.04 | $9.61 |
| 52 Week High | $61.95 | $21.00 |
| Indicator | BLBD | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 65.03 |
| Support Level | $46.44 | $17.90 |
| Resistance Level | $47.89 | $18.73 |
| Average True Range (ATR) | 1.34 | 0.55 |
| MACD | -0.29 | -0.03 |
| Stochastic Oscillator | 25.33 | 79.92 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.